C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma

por Mahner, S, Baasch, C, Schwarz, J, Hein, S, Wölber, L, Jänicke, F, Milde-Langosch, K
Publicado 2008

Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion.

por Kobayashi, H., Ohi, H., Shinohara, H., Sugimura, M., Fujii, T., Terao, T., Schmitt, M., Goretzki, L., Chucholowski, N., Jänicke, F.
Publicado 1993

Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up

por Harbeck, N, Dettmar, P, Thomssen, C, Berger, U, Ulm, K, Kates, R, Höfler, H, Jänicke, F, Graeff, H, Schmitt, M
Publicado 1999

Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer

por Dose-Schwarz, J, Tiling, R, Avril-Sassen, S, Mahner, S, Lebeau, A, Weber, C, Schwaiger, M, Jänicke, F, Untch, M, Avril, N
Publicado 2010

Expression Levels of Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) in Primary Breast Carcinoma and Distant Breast Cancer Metastases

por Ihnen, M., Köhler, N., Kersten, J. F., Milde-Langosch, K., Beck, K., Höller, S., Müller, V., Witzel, I., Jänicke, F., Kilic, E.
Publicado 2010

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc

por Kuhn, W, Schmalfeldt, B, Reuning, U, Pache, L, Berger, U, Ulm, K, Harbeck, N, Späthe, K, Dettmar, P, Höfler, H, Jänicke, F, Schmitt, M, Graeff, H
Publicado 1999

c-FOS suppresses ovarian cancer progression by changing adhesion

por Oliveira-Ferrer, L, Rößler, K, Haustein, V, Schröder, C, Wicklein, D, Maltseva, D, Khaustova, N, Samatov, T, Tonevitsky, A, Mahner, S, Jänicke, F, Schumacher, U, Milde-Langosch, K
Publicado 2014

Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer

por Ihnen, M, Wirtz, R M, Kalogeras, K T, Milde-Langosch, K, Schmidt, M, Witzel, I, Eleftheraki, A G, Papadimitriou, C, Jänicke, F, Briassoulis, E, Pectasides, D, Rody, A, Fountzilas, G, Müller, V
Publicado 2010

External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 in...

por Sweep, C. G., Geurts-Moespot, J., Grebenschikov, N., de Witte, J. H., Heuvel, J. J., Schmitt, M., Duffy, M. J., Jänicke, F., Kramer, M. D., Foekens, J. A., Brünner, N., Brugal, G., Pedersen, A. N., Benraad, T. J.
Publicado 1998

Partial PTEN deletion is linked to poor prognosis in breast cancer

por Lebok, P., Kopperschmidt, V., Kluth, M., Hube-Magg, C., Özden, C., B., Taskin, Hussein, K., Mittenzwei, A., Lebeau, A., Witzel, I., Wölber, L., Mahner, S., Jänicke, F., Geist, S., Paluchowski, P., Wilke, C., Heilenkötter, U., Simon, Ronald, Sauter, Guido, Terracciano, L., Krech, R., von d. Assen, A., Müller, V., Burandt, E.
Publicado 2015